androgen receptor antagonist TAS3681
An orally bioavailable inhibitor of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR inhibitor TAS3681 specifically binds to AR. This prevents AR activation, downregulates AR and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.
Synonym: | androgen receptor inhibitor TAS3681 AR antagonist TAS3681 |
---|---|
Code name: | TAS 3681 TAS3681 |